BBIO News and Press, BridgeBio Pharma Inc. From 02/23/23

–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 trial of low-dose infigrat...

Summary BridgeBio has some very significant price catalysts arriving in 2023 promising substantial upside should they be positive. Most important is Phase 3 interim data from Part B of a pivotal study of Acoramidis - indicated for ATTR. A $3bn market today, ATTR is expected to be wo...

PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will hos...

PALO ALTO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will par...

Summary BridgeBio Pharma, Inc. has a lot of irons in the fire. Despite BridgeBio Pharma, Inc. getting approvals for two products, there's hardly any revenue. None of the BridgeBio Pharma, Inc. products stand out. For further details see: BridgeBio Pharma: T...

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pre...

Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...

BridgeBio Pharma ( NASDAQ: BBIO ) said it started a phase 3 trial of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). Patients with ADH1 have low blood calcium (hypocalcemia), inappropriately low parathyroid hormone levels, and excess excretion of calcium ...

- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week treatment period in patients with autosomal dominant hypocalcemia type 1 (ADH1) ...

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team wi...